Characterization of APOBEC3 variation in a population of HIV-1 infected individuals in northern South Africa.


Journal

BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552

Informations de publication

Date de publication:
19 01 2019
Historique:
received: 02 07 2018
accepted: 21 12 2018
entrez: 21 1 2019
pubmed: 21 1 2019
medline: 21 8 2019
Statut: epublish

Résumé

The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3) genes A3D, A3F, A3G and A3H have all been implicated in the restriction of human immunodeficiency virus type 1 (HIV-1) replication. Polymorphisms in these genes are likely to impact viral replication and fitness, contributing to viral diversity. Currently, only a few studies indicate that polymorphisms in the A3 genes may be correlated with infection risk and disease progression. To characterize polymorphisms in the coding regions of these APOBEC3 genes in an HIV-1 infected population from the Limpopo Province of South Africa, APOBEC3 gene fragments were amplified from genomic DNA of 192 HIV-1 infected subjects and sequenced on an Illumina MiSeq platform. SNPs were confirmed and compared to SNPs in other populations reported in the 1000 Genome Phase III and HapMap databases, as well as in the ExAC exome database. Hardy-Weinberg Equilibrium was calculated and haplotypes were inferred using the LDlink 3.0 web tool. Linkage Disequilibrium (LD) for these SNPS were calculated in the total 1000 genome and AFR populations using the same tool. Known variants compared to the GRCh37 consensus genome sequence were detected at relatively high frequencies (> 5%) in all of the APOBEC3 genes. A3H showed the most variation, with several of the variants present in both alleles in almost all of the patients. Several minor allele variants (< 5%) were also detected in A3D, A3F and A3G. In addition, novel R6K, L221R and T238I variants in A3D and I117I in A3F were observed. Four, five, four, and three haplotypes were identified for A3D, A3F, A3G, and A3H respectively. The study showed significant polymorphisms in the APOBEC3D, 3F, 3G and 3H genes in our South African HIV1-infected cohort. In the case of all of these genes, the polymorphisms were generally present at higher frequencies than reported in other 1000 genome populations and in the ExAC exome consortium database .

Sections du résumé

BACKGROUND
The apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like 3 (APOBEC3) genes A3D, A3F, A3G and A3H have all been implicated in the restriction of human immunodeficiency virus type 1 (HIV-1) replication. Polymorphisms in these genes are likely to impact viral replication and fitness, contributing to viral diversity. Currently, only a few studies indicate that polymorphisms in the A3 genes may be correlated with infection risk and disease progression.
METHODS
To characterize polymorphisms in the coding regions of these APOBEC3 genes in an HIV-1 infected population from the Limpopo Province of South Africa, APOBEC3 gene fragments were amplified from genomic DNA of 192 HIV-1 infected subjects and sequenced on an Illumina MiSeq platform. SNPs were confirmed and compared to SNPs in other populations reported in the 1000 Genome Phase III and HapMap databases, as well as in the ExAC exome database. Hardy-Weinberg Equilibrium was calculated and haplotypes were inferred using the LDlink 3.0 web tool. Linkage Disequilibrium (LD) for these SNPS were calculated in the total 1000 genome and AFR populations using the same tool.
RESULTS
Known variants compared to the GRCh37 consensus genome sequence were detected at relatively high frequencies (> 5%) in all of the APOBEC3 genes. A3H showed the most variation, with several of the variants present in both alleles in almost all of the patients. Several minor allele variants (< 5%) were also detected in A3D, A3F and A3G. In addition, novel R6K, L221R and T238I variants in A3D and I117I in A3F were observed. Four, five, four, and three haplotypes were identified for A3D, A3F, A3G, and A3H respectively.
CONCLUSIONS
The study showed significant polymorphisms in the APOBEC3D, 3F, 3G and 3H genes in our South African HIV1-infected cohort. In the case of all of these genes, the polymorphisms were generally present at higher frequencies than reported in other 1000 genome populations and in the ExAC exome consortium database .

Identifiants

pubmed: 30660178
doi: 10.1186/s12881-018-0740-4
pii: 10.1186/s12881-018-0740-4
pmc: PMC6339282
doi:

Substances chimiques

APOBEC3H protein, human EC 3.5.4.-
Aminohydrolases EC 3.5.4.-
APOBEC3F protein, human EC 3.5.4.1
Cytosine Deaminase EC 3.5.4.1
APOBEC-3G Deaminase EC 3.5.4.5
APOBEC3D protein, human EC 3.5.4.5
APOBEC3G protein, human EC 3.5.4.5
Cytidine Deaminase EC 3.5.4.5

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Pagination

21

Subventions

Organisme : FIC NIH HHS
ID : D43 TW006578
Pays : United States

Références

J Virol. 2005 Sep;79(17):11513-6
pubmed: 16103203
Nature. 2002 Aug 8;418(6898):646-50
pubmed: 12167863
Nat Protoc. 2014 Jan;9(1):171-81
pubmed: 24385147
Science. 2009 May 22;324(5930):1035-44
pubmed: 19407144
Nature. 2010 Oct 28;467(7319):1061-73
pubmed: 20981092
J Virol. 2011 Nov;85(21):11361-71
pubmed: 21835794
Nat Rev Immunol. 2004 Nov;4(11):868-77
pubmed: 15516966
J Virol. 2010 Sep;84(18):9613-7
pubmed: 20592068
Cell Host Microbe. 2013 Oct 16;14(4):411-21
pubmed: 24139399
Bioinformatics. 2016 Oct 1;32(19):3047-8
pubmed: 27312411
S Afr Med J. 2016 May 25;106(6 Suppl 1):S119-23
pubmed: 27245545
Nat Rev Genet. 2002 May;3(5):370-9
pubmed: 11988762
Nature. 2008 Feb 21;451(7181):998-1003
pubmed: 18288195
Cell Host Microbe. 2008 Sep 11;4(3):249-59
pubmed: 18779051
Science. 2008 Feb 22;319(5866):1100-4
pubmed: 18292342
PLoS Pathog. 2012;8(7):e1002800
pubmed: 22807680
Virology. 2013 Sep 1;443(2):329-37
pubmed: 23755966
PLoS Genet. 2016 Mar 04;12(3):e1005921
pubmed: 26942578
J Virol. 2010 Jan;84(1):88-95
pubmed: 19828612
PLoS One. 2012;7(7):e38771
pubmed: 22859935
Nature. 2003 Jul 3;424(6944):94-8
pubmed: 12808465
FASEB J. 2009 Jan;23(1):279-87
pubmed: 18827027
Nat Rev Genet. 2002 Aug;3(8):611-21
pubmed: 12154384
PLoS Genet. 2014 Nov 20;10(11):e1004761
pubmed: 25411794
PLoS One. 2016 Jan 07;11(1):e0146386
pubmed: 26741797
J Virol. 2006 Nov;80(21):10522-33
pubmed: 16920826
J Virol. 2011 Apr;85(7):3142-52
pubmed: 21270145
J Virol. 2009 Jan;83(1):295-303
pubmed: 18945781
Bioinformatics. 2015 Jul 1;31(13):2202-4
pubmed: 25701572
Am J Phys Anthropol. 2002 Oct;119(2):175-85
pubmed: 12237937
J Virol. 2010 Aug;84(16):7961-9
pubmed: 20519396
Fly (Austin). 2012 Apr-Jun;6(2):80-92
pubmed: 22728672
Annu Rev Immunol. 2008;26:317-53
pubmed: 18304004
J Virol. 2004 Oct;78(20):11070-6
pubmed: 15452227
J Virol. 2010 Feb;84(4):1902-11
pubmed: 19939923
Sci Am. 1991 Nov;265(5):104-10
pubmed: 1785035
J Virol. 2011 Nov;85(21):11220-34
pubmed: 21835787
Science. 2002 Dec 20;298(5602):2381-5
pubmed: 12493913
J Biol Chem. 2011 Apr 1;286(13):11415-26
pubmed: 21300806
J Anthropol Sci. 2010;88:73-92
pubmed: 20834051
AIDS. 2010 Jan 16;24(2):195-204
pubmed: 19996938
Bioinformatics. 2009 Aug 15;25(16):2078-9
pubmed: 19505943
Bioinformatics. 2015 Nov 1;31(21):3555-7
pubmed: 26139635
PLoS Comput Biol. 2013;9(7):e1003153
pubmed: 23874191
Nat Genet. 2007 Jul;39(7 Suppl):S30-6
pubmed: 17597779

Auteurs

Nontokozo D Matume (ND)

Myles H. Thaler Center for AIDS and Human Retrovirus Research, Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.
HIV/AIDS & Global Health Research Programme and Department of Microbiology, University of Venda, Thohoyandou, South Africa.

Denis M Tebit (DM)

Myles H. Thaler Center for AIDS and Human Retrovirus Research, Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.
HIV/AIDS & Global Health Research Programme and Department of Microbiology, University of Venda, Thohoyandou, South Africa.
Global Biomed Scientific LLC, PO Box 2368, Forest, VA, 24551, USA.

Laurie R Gray (LR)

Myles H. Thaler Center for AIDS and Human Retrovirus Research, Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.

Stephen D Turner (SD)

Department of Public Health Sciences and Bioinformatics Core, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.

David Rekosh (D)

Myles H. Thaler Center for AIDS and Human Retrovirus Research, Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.
HIV/AIDS & Global Health Research Programme and Department of Microbiology, University of Venda, Thohoyandou, South Africa.

Pascal O Bessong (PO)

HIV/AIDS & Global Health Research Programme and Department of Microbiology, University of Venda, Thohoyandou, South Africa. bessong@univen.ac.za.

Marie-Louise Hammarskjöld (ML)

Myles H. Thaler Center for AIDS and Human Retrovirus Research, Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA. mh7g@virginia.edu.
HIV/AIDS & Global Health Research Programme and Department of Microbiology, University of Venda, Thohoyandou, South Africa. mh7g@virginia.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH